Biossimilares em oncologia.

Sérgio Barroso(Hospital do Espírito Santo), Adriana Teixeira, José Dinis(Instituto Português de Oncologia Francisco Gentil), Helena Gervásio(Instituto Português de Oncologia de Coimbra Francisco Gentil), Margarida Damasceno, A Parreira(IPO Porto), Anabela Sá, Fernando Leal da Costa(University of Alabama at Birmingham), Helena Rodrigues, Ana Marques Pereira, Fernando Prı́ncipe, Jorge Coutinho, João F. Lacerda(University of Lisbon)

DOAJ (DOAJ: Directory of Open Access Journals)

June 1, 2009

10.20344/amp.1706

Cited by 1

Related Papers

Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936

|Leukemia|2003|3k

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

|The Lancet|2018|1.7k

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

|Annals of Oncology|2012|1.5k

Genetic PTX3 Deficiency and Aspergillosis in Stem-Cell Transplantation

|New England Journal of Medicine|2014|301

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

|The Lancet Oncology|2021|266